| Name | Title | Contact Details |
|---|
The Fisher Wallace Stimulator® is a wearable neurostimulation device cleared by the FDA to treat depression, anxiety and insomnia. During each 20-minute treatment session, the device gently stimulates the brain to produce serotonin and other neurochemi...
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides` headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.
QRxPharma Limited is a Bedminster, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Frontida BioPharm is a Minority-Owned Contract Development & Manufacturing Organization. We work collaboratively with our clients to bring new and improved products to the pharmaceutical market. By leveraging our team`s vast knowledge and experience we are able to improve the success of our client`s business and product development efforts. Frontida was launched by founding management team members of Frontage Laboratories. Having 15 years of success in the business Frontage remains a thriving CRO that has become a full service R&D organization located in PA, NJ, and China. With strong record of FDA compliance and quality service to global pharmaceutical and biotechnology companies, the Frontage team easily founded Frontida. While Frontage and Frontida remain affiliates, they are separate business entities.